RFG Advisory LLC Takes Position in Insulet Co. (NASDAQ:PODD)

RFG Advisory LLC bought a new position in Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 948 shares of the medical instruments supplier’s stock, valued at approximately $247,000.

Several other institutional investors have also recently bought and sold shares of the business. Blue Trust Inc. raised its holdings in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares during the last quarter. Venturi Wealth Management LLC boosted its holdings in Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 133 shares during the last quarter. Friedenthal Financial bought a new stake in Insulet in the 4th quarter worth about $57,000. TD Private Client Wealth LLC increased its stake in Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 56 shares during the last quarter. Finally, Versant Capital Management Inc lifted its position in shares of Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 157 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Raymond James increased their price target on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Wells Fargo & Company lifted their target price on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Morgan Stanley increased their price target on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. JPMorgan Chase & Co. lifted their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Finally, Barclays raised their price target on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $272.81.

Insider Activity

In related news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Insulet Trading Up 0.0 %

Shares of PODD opened at $275.97 on Wednesday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $282.87. The company has a market capitalization of $19.36 billion, a P/E ratio of 47.26, a P/E/G ratio of 3.50 and a beta of 1.22. The firm’s 50 day simple moving average is $267.83 and its 200 day simple moving average is $236.83.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. The company had revenue of $543.90 million during the quarter, compared to the consensus estimate of $518.50 million. Insulet had a net margin of 21.22% and a return on equity of 27.98%. During the same period in the previous year, the firm posted $0.71 EPS. Sell-side analysts forecast that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.